全文获取类型
收费全文 | 16200篇 |
免费 | 3321篇 |
国内免费 | 123篇 |
专业分类
耳鼻咽喉 | 273篇 |
儿科学 | 564篇 |
妇产科学 | 534篇 |
基础医学 | 1453篇 |
口腔科学 | 130篇 |
临床医学 | 2096篇 |
内科学 | 4316篇 |
皮肤病学 | 525篇 |
神经病学 | 1125篇 |
特种医学 | 412篇 |
外科学 | 3765篇 |
综合类 | 263篇 |
一般理论 | 12篇 |
预防医学 | 1264篇 |
眼科学 | 649篇 |
药学 | 821篇 |
中国医学 | 87篇 |
肿瘤学 | 1355篇 |
出版年
2023年 | 741篇 |
2022年 | 104篇 |
2021年 | 453篇 |
2020年 | 521篇 |
2019年 | 358篇 |
2018年 | 914篇 |
2017年 | 909篇 |
2016年 | 826篇 |
2015年 | 813篇 |
2014年 | 1077篇 |
2013年 | 1063篇 |
2012年 | 910篇 |
2011年 | 880篇 |
2010年 | 831篇 |
2009年 | 960篇 |
2008年 | 781篇 |
2007年 | 741篇 |
2006年 | 729篇 |
2005年 | 660篇 |
2004年 | 590篇 |
2003年 | 501篇 |
2002年 | 477篇 |
2001年 | 471篇 |
2000年 | 373篇 |
1999年 | 359篇 |
1998年 | 179篇 |
1997年 | 214篇 |
1996年 | 162篇 |
1995年 | 153篇 |
1994年 | 122篇 |
1993年 | 70篇 |
1992年 | 206篇 |
1991年 | 174篇 |
1990年 | 153篇 |
1989年 | 127篇 |
1988年 | 134篇 |
1987年 | 118篇 |
1986年 | 100篇 |
1985年 | 66篇 |
1984年 | 53篇 |
1983年 | 66篇 |
1982年 | 48篇 |
1981年 | 32篇 |
1980年 | 28篇 |
1979年 | 70篇 |
1978年 | 32篇 |
1977年 | 35篇 |
1976年 | 28篇 |
1974年 | 28篇 |
1973年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
2.
3.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
4.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
5.
Bobo H. P. Lau Ting-Kin Ng Yat-Lui Fung Tai-Chung Lam Tsz-Him So 《Journal of psychosocial oncology》2020,38(4):389-405
AbstractPurposes/objectives: This paper reports the comparative efficacies of integrative body-mind-spirit intervention (I-BMS) and cognitive behavioral therapy (CBT) in patient-caregiver parallel groups for Chinese patients with lung cancer.Design: Randomized controlled trial (RCT).Methods: One hundred and fifty-seven patient-caregiver dyads with no marked functional impairment were randomized into one of the two interventions with eight weekly patient-caregiver parallel groups. Assessments were conducted at baseline, within one, eight- and sixteen-weeks post-intervention. Effects of treatment group across time were analyzed by multilevel modeling.Findings: CBT led to greater reduction in emotional vulnerability than I-BMS. I-BMS resulted in greater increase in overall QoL and spiritual self-care, and more reduction in depression than CBT. Patients in both interventions experienced improvement in physical, emotional and spiritual, except social, domains of QoL.Conclusion: I-BMS was more efficacious for diverse domains of QoL, and CBT was more effective for emotional well-being, despite the relatively small between-group effect sizes.Implications for psychosocial providers/policy: (1) With the expanding repertoire of psychosocial interventions for families facing lung cancer, it has become imperative to investigate the comparative efficacies of empirically supported and culturally adapted interventions. (2) Our findings show that I-BMS was more effective for diverse domains of QoL, while CBT was more efficacious with emotional well-being, although both interventions led to significant improvements in physical, emotional and spiritual domains of patient QoL. (3) Patient-caregiver parallel groups have been shown to be effective for enhancing QoL of Chinese lung cancer patients. (4) Care professionals are encouraged to dispense interventions based on the idiosyncratic needs and preferences of the patients to maximize the treatment effects. 相似文献
6.
Malinda Itchins Brandon Lau Amanda L. Hudson Helen Westman Cathy Yi Xia Sarah A. Hayes Viive M. Howell Michael Rodriguez Wendy A. Cooper Heng Wei Michael Buckland Bob T. Li Mark Li Vivek Rathi Stephen B. Fox Anthony J. Gill Stephen J. Clarke Michael J. Boyer Nick Pavlakis 《The oncologist》2020,25(8):641-649
7.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75
8.
9.